Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Twitter
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Night-shift work and breast cancer risk: potential biological mechanism identified
  • News

Night-shift work and breast cancer risk: potential biological mechanism identified

  • 6 July 2020
  • Adriana Albini
Night-shift work and breast cancer risk: potential biological mechanism identified
Total
0
Shares
0
0
0
0
0

Is night-shift work a risk factor for breast cancer? Experimental research just published in Nature Communications gives the molecular basis for asserting that it may well be.

Researchers at Paris-Saclay University, with colleagues from Inserm and Inrae, studied the association between night work and increased tumour aggressiveness. They created a simulated jet-lag situation for mice that reproduced a change in the rhythm between day and night. The collaborative teams observed how disturbances in the circadian rhythm had an impact on breast cancer stem cells and the development of breast tumours. In particular they detected an increased spread of cancer cells and the formation of metastases. They speculated that this is related to increased inflammation. The higher expression of chemokines in circadian-disturbed mice induced infiltration of pro-inflammatory myeloid cells in the microenvironment, causing suppression of adaptive immunity.

Several mechanisms have been postulated before to explain an association between night work and breast cancer, with inhibition of the hormone melatonin by the use of artificial light at night widely seen as the most likely (eg Hansen J, Curr Environ Health Rep 2017).
In the study published in Nature Communications, the use of a chemokine receptor inhibitory drug, which influences the neutrophils and myeloid cells, limited the effect on tumour progression, confirming a role for inflammation.

The topic is controversial. In June 2019, a working group convened by the International Agency for Research on Cancer (IARC) concluded that “night shift work” is “probably carcinogenic to humans” (a Group 2A carcinogen). A paper by the Department of Hygiene and Epidemiology of the Medical University of Łódź, Poland, published the following January (Int J Environ Res Public Health, 2020), found a significantly higher risk of cancer among people working at night. However, other studies have found little or no correlation at all. Exactly a year ago (7 July 2020) Lancet Oncology reported a new cohort study concluding that night shift work does not increase the risk of breast cancer.

The evidence from the Nature Communications study provides important additional evidence to support the proposition that such a link does exist, and about the molecular mechanism involved.

Risk factors for breast cancer are multiple: hereditary (mostly BRCA1 and 2 genes), behavioural (smoke, pollution, parity, lactation) or related to poor nutrition or alcohol consumption. Hormonal factors play an obvious role. There is still a long way to go to understand the influence of time-shifts and work-related stress.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • breast cancer
  • circadian rhythms
  • risk factors
  • shift work
Adriana Albini

Adriana Albini is scientific collaborator at the European Institute of Oncology (IEO) in Milan, Professor of General Pathology at the Milan Bicocca University, she has been deputy Chief of Genoa Cancer Center and Head of Research Department of Reggio Emilia Cancer Center and Scientific Director of MultiMedica Onlus.

Previous Article
  • Articles
  • Featured

Guiding career paths from trainee doctor to oncology leader

  • 6 July 2020
  • Anna Wagstaff
View Post
Next Article
  • In the Hot Seat

Solange Peters: ESMO President

  • 6 July 2020
  • Editorial Staff
View Post
You May Also Like
View Post
  • News

Key link identified in mechanism promoting lung metastases from breast cancer

  • Janet Fricker
  • 17 February 2025
View Post
  • News

OncoDaily Acquires CancerWorld: A New Era in Oncology Media

  • Christopher Greenberg
  • 22 January 2025
View Post
  • News

Second-generation BTK inhibitor shows promise as fixed-duration therapy in CLL

  • Janet Fricker
  • 18 December 2024
View Post
  • News

New evidence can help inform decisions on managing early-onset breast cancer linked to BRCA mutations

  • Janet Fricker
  • 18 December 2024
View Post
  • News

Gut microbiota influence effectiveness of tamoxifen in breast cancer

  • Janet Fricker
  • 6 December 2024
View Post
  • News

Radiotherapy prior to immunotherapy is the best treatment sequence for melanoma related brain metastases

  • Janet Fricker
  • 6 December 2024
View Post
  • News

Study helps solve the puzzle of checkpoint inhibitor myocarditis

  • Janet Fricker
  • 22 November 2024
View Post
  • News

Smoking cessation fundamental to first-line cancer care

  • Janet Fricker
  • 21 November 2024
search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Key link identified in mechanism promoting lung metastases from breast cancer
    • 17 February 2025
  • OncoDaily Acquires CancerWorld: A New Era in Oncology Media
    • 22 January 2025
  • Second-generation BTK inhibitor shows promise as fixed-duration therapy in CLL
    • 18 December 2024
  • New evidence can help inform decisions on managing early-onset breast cancer linked to BRCA mutations
    • 18 December 2024
  • Gut microbiota influence effectiveness of tamoxifen in breast cancer
    • 6 December 2024
Article
  • China’s integrated cancer care guidelines ‘reflect self-confidence’ in the field of oncology
    • 15 February 2025
  • Europe’s cancer agenda: how we keep it a priority in changing times
    • 20 December 2024
  • Humour: an essential tool in cancer care and communication
    • 18 December 2024
Social

Would you follow us ?

Contents
  • Stella Kyriakides: using her voice to improve health in Europe
    • 22 November 2024
  • Bulgarian oncologist Assia Konsoulova
    Assia Konsoulova: improving Bulgaria’s cancer system one oasis at a time
    • 8 November 2024
  • Mohit Singh and his mother Amrita: they are the protagonists of a long and ultimately unsuccessful journey across India in search of cures for her cancer
    ‘I feel guilty sometimes’: a young carer reflects on three years of a losing battle to save his mum
    • 24 October 2024
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.